Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine

Document Details

Document Type
Pub Defense Publication
Publication Date
Mar 01, 2021
Source ID
10.1016/j.jaip.2020.08.039

Entities

People

  • Andrew Menzies-gow
  • Eric S. Bradford
  • Ian D. Pavord
  • Mark T Dransfield
  • Njira Lugogo
  • Oliver N. Keene
  • Pascal Chanez
  • Roland Buhl
  • Steve W. Yancey

Organizations

  • Aeglea BioTherapeutics
  • American Lung Association
  • AstraZeneca
  • Boehringer Ingelheim (United States)
  • Boston Scientific
  • Chiesi Farmaceutici S.p.A.
  • GSK
  • Hoffmann-La Roche
  • Johnson & Johnson
  • MSD (United Kingdom)
  • Merck & Co.
  • National Institutes of Health
  • Novartis
  • Regeneron Pharmaceuticals
  • Roche (United States)
  • Sanofi-Aventis
  • Teva- Pharmaceutical Industries Ltd.
  • United States Department of Defense
  • United States Department of Veterans Affairs